Certara (CERT) Stock Analysis & Winston Score

Certara helps drug companies develop and get approval for new medicines faster using computer software and science. Instead of running every experiment in a lab, drugmakers use Certara's tools to simulate how a drug behaves inside the human body — predicting things like dosing and safety. Its main customers are pharmaceutical and biotech companies, as well as regulatory agencies like the FDA, and it operates in the specialized field of biosimulation and regulatory science. Certara earns money through software subscriptions and technology-enabled services, where its scientists help clients directly with drug submissions and clinical trial design. The company operates globally, with customers across North America, Europe, and Asia, and generated roughly $370 million in annual revenue in recent periods. Its competitive moat comes from deep regulatory expertise and widely adopted software platforms like Phoenix and Simcyp, but its main risk is that slower drug development activity across the biotech industry — driven by funding shortages or regulatory uncertainty — can quickly reduce demand for its services.